2.7.11.1 (5-oxo-5,6-dihydroindolo[1,2-a]quinazolin-7-yl)acetic acid i.e. IQA 24336 2.7.11.1 (5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-2-thioxoimidazolidin-4-one - 158829 2.7.11.1 (S)-2-(2-aminopyrimidiny-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridinione - 80122 2.7.11.1 (Z)-5-(4-propoxybenzylidene) thiazolidine-2,4-dione a Pim-2 inhibitor 172153 2.7.11.1 1,1'-[(5-chloropyrimidine-2,4-diyl)bis[azanediyl(3-methoxy-4,1-phenylene)piperazine-4,1-diyl]]di(ethan-1-one) - 254755 2.7.11.1 1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine i.e. ML-9, 0.5-1.0 mM, 50% inhibition 169802 2.7.11.1 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine i.e. H-7 169803 2.7.11.1 1-(6-[[4-(2,3-dihydro-1H-indol-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-5-methoxy-2,3-dihydro-1H-indol-1-yl)-2-(dimethylamino)ethan-1-one - 254826 2.7.11.1 1-(beta-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole TDB, a cell-permeable selective inhibitor of CK2, inhibits the phosphorylation of OTUB1 at Ser16. In addition to CK2, TDB inhibits 3 other kinases, namely PIM1, CLK2 and DYRK1A, but none of these kinases phosphorylates OTUB1 in vitro 220859 2.7.11.1 1-oleoyl-2-acetylglycerol inhibits phorbol ester binding 110020 2.7.11.1 1-[3-methoxy-4-([6-[2-(propane-2-sulfonyl)anilino]-7H-purin-2-yl]amino)phenyl]piperidin-4-ol - 254903 2.7.11.1 14-3-3beta a p90 ribosomal S6 kinase isoform 1-binding protein that negatively regulates RSK1 kinase activity, interaction via Lys49 of 14-3-3beta and S154 of phosphorylated RSK1, phosphorylation of RSK1 is required for interaction, no binding of mutant 14-3-3beta K49Q or K49A 127447 2.7.11.1 2,3-difluoro-6-[(2-[2-methoxy-4-[4-(propan-2-yl)piperazin-1-yl]anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide - 254942 2.7.11.1 2-(2-aminopyrimidin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one - 79068 2.7.11.1 2-([5-bromo-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino)-N-methylbenzene-1-sulfonamide - 255146 2.7.11.1 2-([5-chloro-2-[2-methoxy-4-(1-methylpiperidin-4-yl)anilino]pyrimidin-4-yl]amino)-N-methylbenzene-1-sulfonamide - 255147 2.7.11.1 2-([5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino)-N-methylbenzene-1-sulfonamide - 255148 2.7.11.1 2-([5-chloro-2-[2-methoxy-4-(morpholin-4-yl)anilino]pyrimidin-4-yl]amino)-N-methylbenzamide - 255149 2.7.11.1 2-([5-chloro-2-[4-(piperazin-1-yl)anilino]pyrimidin-4-yl]amino)-N-methylbenzamide - 255150 2.7.11.1 2-Aminopurine - 6419 2.7.11.1 2-chloro-N-(4-(5-fluoro-2-(4-hydroxyphenylamino)pyrimidin-4-ylamino)phenyl)benzamide - 80124 2.7.11.1 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole i.e DMAT 24335 2.7.11.1 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole i.e. DMAT 24335 2.7.11.1 2-fluoro-6-([2-[(5-methoxy-1-[[4-(propan-2-yl)piperazin-1-yl]acetyl]-2,3-dihydro-1H-indol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino)benzamide - 255209 2.7.11.1 2-fluoro-6-[(2-[2-methoxy-4-[4-(propan-2-yl)piperazin-1-yl]anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzoic acid - 255210 2.7.11.1 2-phenyl-5-(pyridin-4-yl)-1H-pyrrole-3-carboxamide - 79233 2.7.11.1 2-[(2-[4-chloro-2-methoxy-5-[(1-propylpiperidin-4-yl)oxy]anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-6-fluorobenzamide - 255255 2.7.11.1 2-[(2-[5-[(N,N-dimethylglycyl)(methyl)amino]-2-methoxy-4-methylanilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-6-fluorobenzamide - 255256 2.7.11.1 2-[(2-[5-[(N,N-dimethylglycyl)amino]-2-methoxy-4-methylanilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-6-fluorobenzamide - 255257 2.7.11.1 2-[(2-[[1-(N,N-dimethylglycyl)-5-methoxy-2,3-dihydro-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-6-fluoro-N-methylbenzamide - 255258 2.7.11.1 3,8-dibromo-7-hydroxy-4-methyl-2H-chromen-2-one i.e. DBC 61954 2.7.11.1 3-[(2-[[1-(N,N-dimethylglycyl)-6-methoxy-1,2,3,4-tetrahydroquinolin-7-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-N-methylpyridine-2-carboxamide - 255438 2.7.11.1 3-[(2-[[1-(N,N-dimethylglycyl)-6-methoxy-1,2,3,4-tetrahydroquinolin-7-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]thiophene-2-carboxamide - 255439 2.7.11.1 3-[(2-[[1-(N,N-dimethylglycyl)-6-methoxy-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]thiophene-2-carboxamide - 255440 2.7.11.1 3-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate - 40343 2.7.11.1 4,5,6,7-tetrabromo-1H-benzotriazole i.e. TBB 9908 2.7.11.1 4,5,6,7-tetrabromobenzimidazole i.e. TBBz or TBI 61952 2.7.11.1 4,5,6,7-tetrabromobenzotriazole - 185214 2.7.11.1 4,5,6,7-tetrabromobenzotriazole an ATP/GTP-competitive inhibitor of CK2 185214 2.7.11.1 4-(2-(4-(2-(4-acetylpiperazin-1-yl)-2-oxoethyl)phenylamino)-5-fluoropyrimidin-4-ylamino)-N-(2-chlorophenyl)benzamide - 40344 2.7.11.1 4-fluoro-2-([2-[2-methoxy-4-(1-propylpiperidin-3-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino)benzamide - 255598 2.7.11.1 4-fluoro-2-([2-[2-methoxy-4-(1-propylpiperidin-4-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino)benzamide - 255599 2.7.11.1 4-hydroxy-trans-2-nonenal i.e. 4-HNE, binds to the enzyme at Lys197 and inhibits its activity by 69% by inhibiting its posttranslational phosphorylation. 4-HNE binding has no effect on the association of LKB1 with its adaptor proteins, sterile-20-related adaptor and mouse protein 25 8563 2.7.11.1 5-chloro-N2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine - 255715 2.7.11.1 5-chloro-N2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-N4-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine - 255716 2.7.11.1 5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine - 255717 2.7.11.1 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine - 255718 2.7.11.1 5-fluoro-2-[(2-[2-methoxy-4-[4-(propan-2-yl)piperazin-1-yl]anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide - 255719 2.7.11.1 5-fluoro-N2,N4-bis(4-methoxyphenyl)pyrimidine-2,4-diamine - 80126 2.7.11.1 5-fluoro-N2,N4-di(m-tolyl)pyrimidine-2,4-diamine - 80125 2.7.11.1 6,7-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)quinazolin-4-amine elicits selective cytotoxic activity against the pancreas ductal adenocarcinoma (PANC-1) cell line 255745 2.7.11.1 6-(3-chlorophenyl)-4-(1H-indazol-5-yl)pyrimidin-2(1H)-one - 78833 2.7.11.1 7,9-dimethyl-8-(prop-2-en-1-yl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine - 158860 2.7.11.1 8-hydroxy-4-methyl-9-nitro-2H-benzo[g]chromen-2-one i.e. NBC 61953 2.7.11.1 alsterpaullone inhibition of AMPK, GSK3beta, S6K1, PKBalpha, PDK1, MAPKAP-K2 4990 2.7.11.1 alsterpaullone weak inhibition of CK1, inhibition of CK2, and slightly of MAPKAP-K1a 4990 2.7.11.1 AMP-PNP ATP analogue adenosine 5'-(beta,gamma-imino)triphosphate 4099 2.7.11.1 apigenin a CKII-specific inhibitor 515 2.7.11.1 apigenin - 515 2.7.11.1 ATP substrate inhibition. At ATP concentrations above 0.1 mM, kinase activity begins to drop until at 100 mM it becomes almost unmeasurable 4 2.7.11.1 auoinhibitory domain of S6K1 - 146861 2.7.11.1 AZD-6738 ATR inhibition sensitizes cancer cells to ionizing radiation and chemotherapeutics agents (cisplatin, carboplatin, gemcitabine and bendamustine) 256773 2.7.11.1 Baicalin one of the major compounds in the Chinese medical herb Scutellaria baicalensis, reduces enzyme expression and activity in badder cancer cells T24 3678 2.7.11.1 benzene 1,2,3,4-tetrakisphosphate - 14424 2.7.11.1 benzene 1,2,3,5-tetrakisphosphate - 14425 2.7.11.1 benzene 1,2,3-trisphosphate - 14422 2.7.11.1 benzene 1,2,4,5-tetrakisphosphate - 14426 2.7.11.1 benzene 1,2,4-trisphosphate - 10050 2.7.11.1 benzene 1,3,5-trisphosphate - 14423 2.7.11.1 biphenyl 2,3',4,5',6-pentakisphosphate - 14427 2.7.11.1 BMS-863233 - 159457 2.7.11.1 Ca2+ - 15 2.7.11.1 Ca2+ mitochondrial kinase, not cytosolic 15 2.7.11.1 Ca2+ not 15 2.7.11.1 Caffeine ATM/ATR inhibition sensitizes cancer cells to ionizing radiation, nonspecific inhibitor for ATM and ATR; ATM/ATR inhibition sensitizes cancer cells to ionizing radiation, nonspecific inhibitor for ATM and ATR 882 2.7.11.1 Catalytic subunit of protein phosphatase 2A - 31189 2.7.11.1 Catalytic subunit of protein phosphatase 2A Mg2+, Mn2+, Ca2+, EDTA, EGTA or vanadate does not; NaCl, diphosphate, phosphate, NaF or ATP protects 31189 2.7.11.1 CKI-7 - 21953 2.7.11.1 CKI-7 half-maximally at 0.0112 mM 21953 2.7.11.1 Co2+ above 30 mM, activating below 20 mM 23 2.7.11.1 CP466722 enzyme (ATM) inhibition sensitizes cancer cells to ionizing radiation, evokes defects in cell cycle checkpoints 256763 2.7.11.1 Ctl peptide - 213637 2.7.11.1 CX-4945 a CK2 inhibitor 220857 2.7.11.1 D-myo-Inositol 1,3,4,5-tetrakisphosphate - 4803 2.7.11.1 diC8-phosphatidylinositol 3,4,5-trisphosphate - 74900 2.7.11.1 DRB - 24449 2.7.11.1 DTT - 177 2.7.11.1 EDTA - 21 2.7.11.1 EDTA complete inhibition 21 2.7.11.1 ellagic acid - 1279 2.7.11.1 EmbR2 EmbR2, a homologue of EmbR, inhibits PknH by binding to at least two of the three threonine sites known to undergo autophosphorylation in PknH which leads to a dose-response inhibition of the autokinase activity. Moreover, EmbR2 inhibits PknH-dependent phosphorylation of EmbR in a dose-dependent manner 71089 2.7.11.1 emodin a CKII-specific inhibitor 3072 2.7.11.1 emodin - 3072 2.7.11.1 enzastaurin activation-related phosphorylation of Y216/Y276 is dramatically decreased following exposure to enzastaurin whereas the inhibitory phosphorylation of S21 is significantly up-regulated in glioma cells. GSK3 inhibition results in glioma cell death and reduced tumorigenicity 25838 2.7.11.1 enzastaurin oral serine/threonine kinase inhibitor 25838 2.7.11.1 erlotinib - 6877 2.7.11.1 ETP-46464 ATR inhibition, sensitizes cancer cells to ionizing radiation and chemotherapeutics agents non-specific inhibitor for ATR 256770 2.7.11.1 FAALS five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex 71093 2.7.11.1 fostriecin protein phosphatase 2A inhibitor fostriecin reverses the memory-impairing effect of CK2alphaWT, it also reverses the effect of CK2alphaWT in decreasing SGK1 phosphorylation 5546 2.7.11.1 gefitinib - 17786 2.7.11.1 genistein - 377 2.7.11.1 GSK2606414 PERK inhibition. Inhibition of PERKdependent, pro-adaptive unfolded protein response signaling pathway 256765 2.7.11.1 GSK2656157 PERK inhibition. Inhibition of PERKdependent, pro-adaptive unfolded protein response signaling pathway 256766 2.7.11.1 H-7 - 35190 2.7.11.1 harmine - 6774 2.7.11.1 heparin inhibition of recombinant casein kinase I delta when phosvitin is the substrate 227 2.7.11.1 heparin inhibition with casein and phosvitin as substrate 227 2.7.11.1 heparin - 227 2.7.11.1 heparin recombinant GST-CK2 catalytic subunit 227 2.7.11.1 heparin strongly inhibits casein kinase II 227 2.7.11.1 heparin a specific inhibitor of CK2 227 2.7.11.1 idelalisib 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4(3H)-one, a PI3Kdelta inhibitor used to treat hematological malignancies. The inhibitor idelalisib is selective, noncovalent, reversible, and ATP-competitive, The compound binds reversibly and noncovalently to the p110delta subunit of the kinase, analysis of binding interactions that confer the potency and selectivity of idelalisib, overview. Idelalisib is a propeller-shaped inhibitor 213206 2.7.11.1 indirubin-3'-monoxime inhibition of AMPK, GSK3beta, S6K1, PKBalpha, PDK1, MAPKAP-K2 9839 2.7.11.1 indirubin-3'-monoxime inhibition of CK1 and MAPKAP-K1a 9839 2.7.11.1 JAK3 inhibitor VI - 40341 2.7.11.1 K-252a - 17792 2.7.11.1 K252a - 10865 2.7.11.1 kaempferol an inhibitor of RSK2 invitro and in vivo, and suppresses proliferation and EGF-induced transformation in JB6 Cl41 cells, overview 408 2.7.11.1 KCl not 79 2.7.11.1 KCl eIF-4E as substrate 79 2.7.11.1 kenpaullone slight inhibition of AMPK, GSK3beta, PKBalpha, PDK1 6875 2.7.11.1 kenpaullone slight inhibition of MAPKAP-K1a 6875 2.7.11.1 KN-93 sselective inhibitor for CaMKII 1996 2.7.11.1 KU-55933 enzyme (ATM) inhibition sensitizes cancer cells to ionizing radiation and DNA DSBs inducing chemotherapeutics agents 256761 2.7.11.1 KU-59403 enzyme (ATM) inhibition significant chemosensitization and radiosensitization 256764 2.7.11.1 KU-60019 enzyme (ATM) inhibition sensitizes cancer cells to ionizing radiation 256762 2.7.11.1 LAALS five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex 25839 2.7.11.1 lithium after inhibition of GSK-3 in cortical neurons, the splicing factor SC35 is nuclearly redistributed and enriched in nuclear speckles and colocalizes with the kinase 6242 2.7.11.1 lithium - 6242 2.7.11.1 luteolin i.e. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromenone, directly inhibits TPL2 activity, luteolin binds to TPL2 in an ATP-competitive manner, binding mode of luteolin, molecular modeling and docking study, overview. Luteolin easily docks to the ATP binding site of TPL2, which is located between the N-lobe and C-lobe of the kinase domain. In a cellular system, phosphorylation of TPL2 is increased by luteolin treatment, and luteolin suppresses TNF-alpha-induced TPL2 activity in JB6 P+ cells 436 2.7.11.1 Ly-294002 - 8561 2.7.11.1 LY294002 PI3K inhibitor 770 2.7.11.1 LY294002 - 770 2.7.11.1 LY294002 enzyme (ATM) inhibition sensitizes cancer cells to ionizing radiation, non-specific inhibitor for ATM 770 2.7.11.1 Mg2+ above 30 mM, activating below 20 mM 6 2.7.11.1 MK2206 W80A mutation confers resistance to the Akt inhibitor MK2206 256767 2.7.11.1 MLN8054 Aurora A-selective inhibitor 80123 2.7.11.1 Mn2+ above 30 mM, activating below 20 mM 11 2.7.11.1 Mn2+ 10 mM Mn2+ inhibits phosphorylation of myelin basic protein by PknB 11 2.7.11.1 additional information no inhibition by cAMP 2 2.7.11.1 additional information heparin, Ca2+/calmodulin, phosphatidylserine and/or diolein (in the absence or presence of Ca2+); protein inhibitor of cAMP-dependent protein kinase (protamine as substrate), monoclonal antibodies to catalytic domain of protein kinase C from rat brain 2 2.7.11.1 additional information cGMP, heat-stable inhibitor of cAMP-dependent protein kinase; EGTA, calmodulin; heparin, Ca2+/calmodulin, phosphatidylserine and/or diolein (in the absence or presence of Ca2+); no inhibition by cAMP 2 2.7.11.1 additional information EGTA, calmodulin; heparin, Ca2+/calmodulin, phosphatidylserine and/or diolein (in the absence or presence of Ca2+) 2 2.7.11.1 additional information protein phosphatase 2B, 2C, catalytic subunit of protein phosphatase 1, protein tyrosine phosphatases (PTPase 1B and T-cell PTPase), pyruvate dehydrogenase phosphatase 2 2.7.11.1 additional information WKN4 possesses an autoinhibitory domain, residues 444-518, the isolated autoinhibitory domainin 1-443 inhibits WKN1 2 2.7.11.1 additional information no inhibition of most serine/threonine kinases by roscovitine 2 2.7.11.1 additional information GSK3 phosphorylation and inhibition by PKB protein kinase at S21 and S9 2 2.7.11.1 additional information no inhibition of S6K2 by wortmannin or rapamycin, S6K2 phosphorylation by MEK of S410, S417, and S423 of the autoinhibition domain leads to inhibition of the enzyme 2 2.7.11.1 additional information enzyme expression level is decreased under low pH and heat shock conditions 2 2.7.11.1 additional information PKN possesses an autoinhibitory site at the C-terminal C2 domain, which also binds activating arachidonic acid 2 2.7.11.1 additional information phosphorylation of GSK3beta at S9 inhibits the enzyme 2 2.7.11.1 additional information phosphorylation at Ser9 by PKGI and PKGII inhibits the glycogen synthase kinase 3 2 2.7.11.1 additional information ORF47 kinase is resistant to heparin, host cell pretreatment prior to virus infection with D,L-alpha-difluoromethylornithine reduces intracellular polyamine concentration and thus inhibits the viral enzyme ORF47 2 2.7.11.1 additional information the pleckstrin homology PH domain is a negative regulator of PKD2 2 2.7.11.1 additional information the chromophoric domain light-oxygen-voltage-sensing 2 LOV2 of phototropin acts as an intramolecular inhibitor to substrate protein phosphorylation 2 2.7.11.1 additional information in vivo inhibition strategies in the mouse model, validation of CK2 targets identification of bona fide targets, overview 2 2.7.11.1 additional information CDPKs contain an autoinhibitory junction region whose calcium-dependent interaction with the tethered regulatory calmodulin-like domain activates the catalytic kinase domain 2 2.7.11.1 additional information inhibition of GSK3 activity results in c-MYC activation, leading to the induction of Bax, Bim, DR4/DR5, and tumor necrosis factor-related apoptosis-inducing ligand expression and subsequent cytotoxicity. inhibition of GSK3 activity causes a dramatic decrease in intracellular nuclear factor-kappaB activity. Inhibition of GSK3 activity results in c-MYC-dependent glioma cell death through multiple mechanisms, all of which converge on the apoptotic pathways 2 2.7.11.1 additional information the p110alpha-mediated increase in AMPK S485/491 phosphorylation is eliminated in the presence of the Akt inhibitor MK2206 2 2.7.11.1 additional information expression of the pleckstrin homology of Akt1 has no significant impact on the ability of picomolar concentrations of cytokine to promote hemopoietic cell survival 2 2.7.11.1 additional information no inhibitin by gefitinib and erlotinib. DMSO at up to 0.1% has no effect on enzyme activity 2 2.7.11.1 additional information Sec2p phosphorylation is affected in Pik1p and Sac1p mutants 2 2.7.11.1 additional information the enzyme is inhibited by high light 2 2.7.11.1 N-(2-chlorophenyl)-4-(2-(4-(2-(4-ethylpiperazin-1-yl)-2-oxoethyl)phenylamino)-5-fluoropyrimidin-4-ylamino)benzamide - 40345 2.7.11.1 N-(2-chlorophenyl)-4-(5-fluoro-2-(4-hydroxyphenylamino)pyrimidin-4-ylamino)benzamide - 80127 2.7.11.1 N-cyclopropyl-4-(5-fluoro-2-(4-hydroxyphenylamino)pyrimidin-4-ylamino)benzamide - 80128 2.7.11.1 N-ethyl-3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-3a,6a-dihydro-1H-thieno[3,2-c]pyrazole-5-carboxamide - 79172 2.7.11.1 N-tert-butyl-3-([5-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino)benzene-1-sulfonamide - 256158 2.7.11.1 N-[(2R)-2,3-dihydroxypropyl]-5-fluoro-2-[(2-[2-methoxy-4-[4-(propan-2-yl)piperazin-1-yl]anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide - 256166 2.7.11.1 N-[2-(4-fluorophenyl)ethyl]-5-[2-[(methylsulfonyl)amino]pyrimidin-4-yl]thiophene-2-carboxamide - 158759 2.7.11.1 N-[2-([5-chloro-2-[2-methoxy-4-(morpholin-4-yl)anilino]pyrimidin-4-yl]amino)phenyl]methanesulfonamide - 256180 2.7.11.1 N-[2-([5-fluoro-2-[2-methoxy-4-(morpholin-4-yl)anilino]pyrimidin-4-yl]amino)phenyl]methanesulfonamide - 256181 2.7.11.1 N-[3-([2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino)phenyl]prop-2-enamide - 256190 2.7.11.1 N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine - 256192 2.7.11.1 N-[5-(4-fluorophenyl)-1H-pyrazol-3-yl]-6,7-dimethoxyquinazolin-4-amine - 256221 2.7.11.1 N2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine - 256235 2.7.11.1 N2-[2-methoxy-4-[4-(propan-2-yl)piperazin-1-yl]phenyl]-N4-(quinolin-5-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine - 256236 2.7.11.1 NaCl bovine serum albumin, not protamine as substrate 42 2.7.11.1 NaCl not 42 2.7.11.1 NaCl eIF-4E 42 2.7.11.1 NU6027 ATR inhibition, sensitizes cancer cells to ionizing radiation and chemotherapeutics agents non-specific inhibitor for ATR 23714 2.7.11.1 NVP-BEZ235 ATR inhibition, sensitizes cancer cells to ionizing radiation and chemotherapeutics agents non-specific inhibitor for ATR 37810 2.7.11.1 O-phosphoprotamine bovine serum albumin, not protamine as substrate 46354 2.7.11.1 O6-cyclohexylmethylguanine - 71090 2.7.11.1 P53 - 2978 2.7.11.1 PF-3758309 - 256768 2.7.11.1 PF670462 a CK1delta/epsilon kinase inhibitor 220858 2.7.11.1 PHA-767491 nanomolar, ATP-competitive, Cdc7 inhibitor 80121 2.7.11.1 phosphatidylinositol-4-phosphate inhibits Sec2p phosphorylation by Yck2p 35305 2.7.11.1 PIK-75 a p110alpha-selective PI3K inhibitor 213203 2.7.11.1 polylysine - 2581 2.7.11.1 polylysine poly-lysine has a substrate-specific inhibitory effect on the CKII alpha subunit, whereas it stimulates the activity of the CKII holoenzyme. Polylysine inhibits RNP29 phosphorylation by CKIIalpha 2581 2.7.11.1 Protein phosphatase 1b weak 98679 2.7.11.1 Protein phosphatase 2A 2A1 and 2; ATP; okadaic acid, microcystin-LR; phosphate or NaF prevents; specific protamine kinase inhibitors 3690 2.7.11.1 Protein phosphatase 2A ATP; diphosphate; Mn2+ enhances inactivation rate; okadaic acid, microcystin-LR; protein phosphatase inhibitor 2 does not protect; rate of inactivation is unaffected by EDTA, EGTA, Mg2+, Ca2+; specific protamine kinase inhibitors 3690 2.7.11.1 Protein phosphatase 2A eIF-4E, 40S ribosomes or protamine as substrate 3690 2.7.11.1 purvalanol inhibition of AMPK, slight inhibition of GSK3beta and S6K1, PKBalpha 8614 2.7.11.1 purvalanol slight inhibition of CK1 and MAPKAP-K1a 8614 2.7.11.1 Ro 31-8220 - 32955 2.7.11.1 roscovitine slight inhibition of PKBalpha and MAPKAP-K2 994 2.7.11.1 roscovitine inhibition of CK1 and MAPKAP-K1a 994 2.7.11.1 SB203580 - 1808 2.7.11.1 SB203580 slight inhibition of the protein kinase 1808 2.7.11.1 SB203580 the p38 MAPK pathway inhibitor inhibits enzyme activity of RIP2 1808 2.7.11.1 spermine bovine serum albumin, not protamine as substrate 197 2.7.11.1 staurosporine - 886 2.7.11.1 staurosporine inhibits phosphorylation of myelin basic proteins 886 2.7.11.1 Su-11248 - 40342 2.7.11.1 TAACS five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex 38213 2.7.11.1 TAALD five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex 71091 2.7.11.1 TAALE five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex 71092 2.7.11.1 tamoxifen - 1629 2.7.11.1 TBCA - 36429 2.7.11.1 Torin 2 ATR inhibition, sensitizes cancer cells to ionizing radiation and chemotherapeutics agents non-specific inhibitor for ATR 256769 2.7.11.1 Toyocamycin toyocamycin binds in the ATP binding pocket of the protein more tightly than ATP/Mg2+ 10797 2.7.11.1 VE-821 ATR inhibition, sensitizes cancer cells to ionizing radiation and chemotherapeutics agents, blocks activation of Chk1-dependent signaling pathway, enhances DNA damage in combination with cisplatin, arrests cell cycle in G2/M phase 256771 2.7.11.1 VE-822 ATR inhibition sensitizes cancer cells to ionizing radiation and chemotherapeutics agents (cisplatin, oxaliplatin, gemcitabine, etoposide and SN38, the active metabolite of irinotecan) 256772 2.7.11.1 wortmanin PI3K inhibitor 146860 2.7.11.1 Wortmannin a specific PI3K inhibitor 631 2.7.11.1 Wortmannin - 631 2.7.11.1 Wortmannin enzyme (ATM) inhibition sensitizes cancer cells to ionizing radiation 631 2.7.11.1 YM024 a p110alpha-selective PI3K inhibitor 213207